Oncotelic Validates Deciparticle™ Tech in Peer-Reviewed Study for IV Everolimus
Event summary
- Oncotelic published a peer-reviewed study in Biomedicines validating its Deciparticle™ technology for IV everolimus (Sapu003) on July 14, 2026.
- The study demonstrated successful ADME, PK, toxicology, and cGMP manufacturing of Sapu003, addressing oral everolimus' pharmacokinetic limitations.
- IV administration showed broad systemic distribution without gastrointestinal accumulation, potentially improving tolerability.
- Sapu003 is currently in a Phase 1b clinical trial (NCT07369505) for advanced mTOR-sensitive solid tumors.
The big picture
Oncotelic's validation of Deciparticle™ technology addresses a critical gap in delivering hydrophobic drugs intravenously, potentially disrupting the oncology space where oral formulations face pharmacokinetic challenges. The success of this platform could position Oncotelic as a key player in nanomedicine, particularly if it secures strategic collaborations for other hydrophobic therapeutics.
What we're watching
- Clinical Progress
- The pace at which Sapu003 advances through Phase 1b and potential expansion into broader oncology indications.
- Platform Scalability
- Whether Deciparticle™ technology can be successfully applied to other hydrophobic therapeutics beyond everolimus.
- Manufacturing Execution
- How Oncotelic scales cGMP manufacturing for Sapu003 and future pipeline candidates under its joint venture with SAPU Bio.
Related topics